Company Profile
iSpecimen Stock Price, News & Analysis
Company overview
Business overview
iSpecimen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, iSpecimen is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
iSpecimen follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, iSpecimen sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ISPC is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
iSpecimen’s catalysts are biospecimen marketplace growth and research-customer adoption. The business improves when the platform becomes more embedded in sourcing workflows.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
iSpecimen to Report Third Quarter 2022 Results on November 8, 2022
Source: iSpecimen
- 03
- 04
iSpecimen Reports Third Quarter 2022 Financial and Operating Results
Source: iSpecimen
- 05
iSpecimen Appoints Joseph J. Basile to Board of Directors
Source: iSpecimen
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.